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Abstract  1 
The association between primary aldosteronism (PA) and obstructive sleep apnea (OSA) has 2 
been a matter of debate. 2016 Endocrine Society guideline recommends screening for PA all 3 
hypertensive patients with OSA.  4 
We designed a multicentre, multi-ethnic, cross-sectional study to evaluate the prevalence of 5 
PA in patients with OSA and the prevalence of OSA in unselected patients with PA. 6 
203 patients with OSA (102 Caucasians and 101 Chinese) were screened for PA and 207 7 
patients with PA (104 Caucasians, 100 Chinese and 3 of African descent) were screened for 8 
OSA by cardio-respiratory polygraphy. Eighteen patients with OSA (8.9%) had PA (11.8% 9 
of Caucasian and 5.9% of Chinese ethnicity). In patients without other indications for PA 10 
screening, the prevalence of PA dropped to 1.5%. The prevalence of OSA in patients with PA 11 
was 67.6%, consistent in both Caucasian and Chinese patients. A correlation between 12 
aldosterone levels and apnea/hypopnea index was observed in Caucasian patients with PA (R
2
 13 
= 0.360, p = 0.013), but not in Chinese patients. Multinomial logistic regression confirmed a 14 
significant and independent association between plasma aldosterone levels and moderate to 15 
severe OSA diagnosis in Caucasian patients (OR 1.002, p=0.002).  16 
In conclusion, aldosterone levels may contribute to the severity of OSA in Caucasian patients 17 
with hyperaldosteronism, but patients with OSA are not at high risk of PA. Results of the 18 
present study challenge the current recommendation of the Endocrine Society guideline that 19 
all patients with OSA should be screened for PA, irrespective of the grade of hypertension.  20 
 21 
 22 
 23 
 24 
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Key words: aldosterone, primary aldosteronism, obstructive sleep apnea, sleep disorders, 1 
apnea-hypopnea index 2 
Introduction 3 
Obstructive sleep apnea (OSA) is the most frequent secondary condition associated with 4 
resistant hypertension (RH).
 1
 Taking into account moderate and severe forms of OSA, the 5 
prevalence among patients with RH ranges from 45% to 80% and up to 95% among patients 6 
with refractory hypertension.
1-5
 Primary aldosteronism (PA) is the most common secondary 7 
endocrine cause of hypertension, and its prevalence can be as high as 20% among patients 8 
with RH.
6
 In agreement with these data, 2017 ACC/AHA hypertension guideline and the 9 
2018 AHA Scientific Statement on Resistant Hypertension recommend screening all patients 10 
with RH for PA.
7,8
 In patients with RH, rostral fluid displacement is related to the severity of 11 
OSA  and treatment with mineralocorticoid receptor (MR) antagonists reduces legs-to-neck 12 
fluid redistribution and the apnea hypopnea index (AHI).
9-11
 It has been speculated that the 13 
high prevalence of OSA in RH patients could be related to the high prevalence of 14 
autonomous aldosterone secretion in this specific subpopulation.
12
 15 
In the last 20 years, several efforts have been devoted to investigate the bidirectional 16 
relationship between aldosterone levels and sleep apnea disorders: some studies identified an 17 
association between aldosterone levels and AHI, or OSA diagnosis, but only in specific 18 
subgroups of patients or exclusively in patients with RH, yielding conflicting results.
13
  19 
Albeit supporting evidence is limited, the 2016 Endocrine Society (ES) guideline recommend 20 
screening for PA all the patients affected by arterial hypertension and OSA.
14
 We report here 21 
the results of the HYpertensives with Primary aldosteronism aNd OSas (HYPNOS) study, 22 
undertaken to investigate the prevalence of PA in a large cohort of Caucasian and Chinese 23 
hypertensive patients with OSA, and the prevalence of OSA in a cohort of Caucasian and 24 
Chinese patients affected by PA. 25 
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Methods 1 
The data that support the findings of this study are available from the corresponding author 2 
upon reasonable request. 3 
Study design and patients 4 
The protocol was approved by the local ethical committees of all the participant centers and 5 
written informed consent was obtained from all patients recruited.  6 
The cohort of the HYPNOS study was enrolled in seven different centers: four Italian centers 7 
(Turin, Ancona, Padova, Verona), one German center (Munich), one Chinese center 8 
(Chongqing), one Taiwanese center (Taipei) (Tables S1). 9 
Between 10/2016 and 09/2018 410 patients were enrolled: 207 affected by PA (Group 1) 10 
(including 104 of Caucasian ethnicity, 100 of Chinese ethnicity and 3 of other origin) and 203 11 
with OSA (Group 2) (102 Caucasians and 101 Chinese). The only criterion for inclusion in 12 
Group 1 was confirmed diagnosis of PA according with the Endocrine Society guideline, 13 
while criteria for inclusion in Group 2 were I) diagnosis of OSA with AHI ≥15 or AHI≥5 14 
together with symptoms requiring Continuous Positive Airway Pressure (CPAP) treatment 15 
(such as daytime somnolence, fatigue, insomnia, mood disorders, or cognitive impairment), 16 
and II) a diagnosis of arterial hypertension according with European Society of 17 
Cardiology/European Society of Hypertension (ESC/ESH) guideline.
14-17
 Criteria for 18 
exclusion were: for Group 1 patients with PA under MRA therapy or previously 19 
adrenalectomized for unilateral primary aldosteronism; for Group 2: any absolute 20 
contraindication to perform a confirmatory test for PA. 21 
All 203 patients diagnosed with OSA were screened for PA and all 207 patients with PA 22 
diagnosis were evaluated for sleeping disorders. 23 
Diagnosis of primary aldosteronism 24 
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PA was diagnosed according to 2016 ES guideline.
14
 All interfering antihypertensive drugs 1 
were stopped at least 2 weeks before screening (at least 4 weeks for diuretics). At least one of 2 
saline infusion test, fludrocortisone suppression test or captopril challenge test was used to 3 
confirm PA diagnosis according to the centre protocol (Table S1). Subtype diagnosis was 4 
performed by computed tomography scanning of the adrenal glands and subsequent adrenal 5 
venous sampling (AVS). AVS data were interpreted according to the centers protocol (Table 6 
S1). 7 
Obstructive sleep apnea measures 8 
Sleep apnea was assessed with a validated cardio-respiratory polygraphy with at least 8 9 
standard channels, recording oronasal flow, snoring, thoracic and abdominal respiratory 10 
movements, finger pulse oximetry, body position, and electrocardiogram. Apnea was defined 11 
as a reduction of oronasal flow ≥90% for ≥10 seconds. Hypopnea was defined as a ≥ 30 % 12 
reduction in oronasal flow for ≥10 seconds, associated with oxygen desaturation of ≥3% or 13 
arousal.
15
 The Apnea Hypopnea Index (AHI) was defined as the total number of apneas plus 14 
hypopneas per hour of recording time. OSA was defined as AHI ≥5 and classified as mild 15 
(AHI ≥5 to <15), moderate (AHI ≥15 to <30), or severe (AHI ≥30). Epworth Sleepiness Scale 16 
(ESS) was administered to assess daytime sleepiness before CPAP treatment. 17 
Hypertension, cardiovascular events, diabetes and metabolic syndrome definition 18 
Blood pressure levels were assessed by three consecutive BP measurements in the sitting 19 
position, according to 2018 ESC/ESH guideline.
16,17
 The list of validated devices used for BP 20 
measurement in the different centers is provided in the Online supplement. We defined 21 
arterial hypertension as systolic blood pressure (SBP) ≥ 140 mmHg and DBP ≥ 90 mmHg 22 
and we classified hypertension in three different grades according to 2018 ESC/ESH 23 
guideline.
16,17
 The intensity of antihypertensive medication was calculated as daily defined 24 
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dose (DDD). We calculate defined daily dose with the online tool available at 1 
https://github.com/ABurrello/PASOPredictor/raw/master/00 - PASO Predictor.xlsm.
18
  2 
Diabetes was defined according to 2015 American Diabetes Association criteria.
19  
3 
Metabolic syndrome was defined according to International Diabetes Federation criteria.
20
 4 
Statistical Analysis.  5 
IBM SPSS Statistics version 25.0 (IBM Corp., Armonk, New York) was used for statistical 6 
analyses. PAC, PRA, ARR, AHI, ESS, triglycerides and GFR data were analyzed with non-7 
parametric test or log transformed due to non-normality, according to Kolmogorov-Smirnov 8 
test. Results are expressed for continuous variables with a normal distribution as mean ± 9 
standard deviation (SD). Non-normal distributions are expressed as median (interquartile 10 
range, IQR). Statistical significance between groups was calculated in normally distributed 11 
data by Student t test for independent samples. Mann-Whitney U test was used for non-12 
normally distributed data and chi-square test or the Fisher exact test for qualitative variables. 13 
Pearson’s correlation was performed to correlate aldosterone and AHI. Logistic regression 14 
models were performed to evaluate the odds ratio (OR) of the available variables for 15 
moderate-severe OSA. All the variables that had p < 0.05 at the univariate analysis or 16 
considered relevant on the basis of the descriptive analysis were included in the multinomial 17 
model. Multinomial logistic regression was performed to predict moderate to severe OSA 18 
diagnosis, correcting for age, sex, ethnicity, waist circumference, neck circumference, 19 
systolic blood pressure (SBP), high-density lipoprotein cholesterol (HDL), triglycerides, 20 
fasting glucose, PA subtype diagnosis, and plasma aldosterone or the categorical variable. 21 
Results 22 
OSA and PA cohorts 23 
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A total of 203 patients with OSA and indication for continuous positive airway pressure 1 
(CPAP) treatment were enrolled. According to AHI, 19 were affected by mild OSA (9.4%), 2 
55 by moderate OSA (27.1%) and 129 by severe OSA (63.5%). 3 
Two hundred and seven patients with PA were recruited: 97 patients were affected by 4 
unilateral aldosterone producing adenoma (APA), 63 by idiopathic hyperaldosteronism (IHA) 5 
and in 47 patients a definitive subtype diagnosis was  not achieved, since the AVS was 6 
unsuccessful, not considered indicated by the treating physicians (for example because of 7 
advanced age) or refused by the patients. Clinical and biochemical parameters of the included 8 
patients are reported in Table 1. 9 
Prevalence of PA in patients with OSA 10 
 The prevalence of PA in patients affected by OSA was 8.9 % (18/203, 95% CI 5.7–13.6), a 11 
figure not significantly different either from the 5.9% (p=0.10) observed in the general 12 
hypertensive population or from the 11.2% of the referral centers (p=0.32).
21,22
   13 
Of note, in our  cohort of patients affected by OSA, 136 out of 203 patients (67%) had at least 14 
another indication for being screened for PA (among SBP above 150 mmHg, DBP above 100 15 
mmHg or hypokalemia), while in 67/203 patients (33%) the presence of OSA was the only 16 
indication. In this latter subgroup, only 1 patient (of Chinese ethnicity) was diagnosed as 17 
affected by PA, resulting in a prevalence of 1.5% (0.3–8.0). 18 
After subtype diagnosis, ten patients were classified as affected by IHA, seven by APA and 19 
one patient, who refused AVS, was classified as undetermined (Figure 1A). 20 
As expected, the prevalence of PA increased with the severity of hypertension: from 2.9% 21 
(1.0–8.1), in grade 1 to 22.0% (12.0–36.7) in grade 3 (p=0.001) (Figure S1A), while it was 22 
not  different in OSA stages (Figure S1B); similarly, in the overall cohort, aldosterone and 23 
PRA levels were not different in the three OSA stages.  24 
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OSA patients with PA showed higher SBP, higher DBP and lower potassium levels compared 1 
with OSA patients without PA, as detailed in Table 2, while no difference was observed in 2 
terms of AHI or sleepiness symptoms.  3 
We analysed factors associated with the diagnosis of PA in OSA cohort in adjusted and 4 
unadjusted analyses (Table S2 and S3): after correction for confounding variables, patients 5 
with higher SBP and lower potassium levels had an increased likelihood of having PA. 6 
Compared with Caucasian OSA cohort, Chinese patients showed increased OSA severity and 7 
sleepiness symptoms and lower SBP and K
+
 levels (Table 3). 8 
The prevalence of PA was 11.8% (6.9–59.4) in Caucasian patients with OSA (12/102) and 9 
5.9% (2.7–12.4;) in the Chinese cohort (6/101) (p=0.144) (Figure 1B-C).  PRA levels were 10 
significantly lower in Caucasians (Table 3), even after exclusion of patients with PA (Table 11 
S4).  12 
Prevalence of OSA in patients with PA 13 
Of the 207 patients with a confirmed diagnosis of PA, 140 (67.6%; 61.0–73.6) had a 14 
diagnosis of OSA: 27.1% mild (21.5–33.5), moderate 21.7% (16.7–27.8) and severe 18.8% 15 
(14.1–24.7) (Figure 2A).  16 
Considering that CPAP treatment is recommended in patients with AHI ≥ 15 even without 17 
symptoms or CV risk factors, we compared PA patients with moderate-severe OSA (AHI ≥ 18 
15) to PA patients with mild or no OSA (AHI < 15), as detailed in Table 2. 19 
While in the overall cohort of patients affected by PA, aldosterone levels did not differ 20 
significantly between patients with moderate-severe OSA and patients with mild or no OSA, 21 
subgroup analysis revealed that Caucasian patients affected by PA and AHI ≥15 had 22 
significantly higher aldosterone levels compared with patients with AHI <15 (802 pmol/L 23 
[IQR 555–1176] vs 646 pmol/L [436–914]; p=0.017), while no difference was present in 24 
Chinese patients with PA (Table S5). 25 
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Prevalence of OSA in patients with PA was similar in Chinese and Caucasian patients (Figure 1 
2B-C), however, according to AHI, Chinese patients showed a more severe phenotype 2 
(p=0.016) (Table 4). 3 
Taking into account only patients with a definitive subtype diagnosis of PA, OSA was more 4 
prevalent in PA patients with IHA than APA (75.8% [63.8–84.7] vs 59.2% [49.3–68.4]; 5 
p=0.031) (Figure S1C and Table S6). Consistently, patients with IHA had a higher BMI 6 
(p=0.002) and waist circumference, among females (p<0.001), compared with unilateral PA 7 
(Table S7). Pearson’s analysis demonstrated a significant correlation between aldosterone 8 
levels and AHI in both unilateral (R
2
=0.360; p=0.013) and bilateral (R
2
=0.362; p=0.013) 9 
forms, and in the overall group of Caucasian patients with PA (R
2
=0.225; p=0.016), but not in 10 
the Chinese cohort (Figure S2-S3). There was no significant association between aldosterone 11 
and AHI in non-PA patients (p=0.443), however, the absence of non-PA patients without 12 
OSA and the presence of few non-PA patients with mild OSA might have affected the results. 13 
Multinomial logistic regression demonstrated a significant association of aldosterone levels 14 
and moderate-severe OSA in all patients with PA (OR 1.001 [95% CI 1.000–1.002]; 15 
p=0.005), after correction for age, sex, waist and neck circumference, SBP, fasting glucose, 16 
HDL, triglycerides lev ls, ethnicity and subtype diagnosis (Tables S8-S9). Interestingly, the 17 
same analysis divided for ethnicity demonstrated a significant association only in Caucasian 18 
(OR 1.002 [1.001–1.003]; p=0.002), but not in Chinese patients with PA (OR 0.998 [0.998–19 
1.002]; p=0.384). Other predictive factors of moderate-severe OSA were male sex and 20 
glucose levels in the Caucasian group with PA, and male sex, waist circumference and age in 21 
Chinese patients (Table S10). 22 
We repeated the same analysis, dichotomizing serum aldosterone levels according with the 23 
median level of the global PA cohort, with a threshold of 750 pmol/l (27.04 ng/dl), 24 
demonstrating an OR of 8.264 (2.410–28.571; p=0.001) for Caucasian patients with 25 
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aldosterone ≥750 pmol/l. In agreement with previous results, no significant difference was 1 
present in Chinese patients with PA (Tables S11-S12). 2 
 3 
Discussion 4 
To the best of our knowledge, the HYPNOS study is the largest study aimed at assessing the 5 
prevalence of PA in a multi-ethnic cohort of patients affected by OSA and the first study 6 
aimed at assessing the prevalence of OSA in unselected patients affected by PA. 7 
The main findings of our study are that, in the overall cohort of hypertensive patients affected 8 
by OSA, the prevalence of primary aldosteronism did not differ significantly from the 9 
prevalence observed in the general hypertensive population, while, in Caucasian patients 10 
affected by PA, aldosterone levels contribute to the severity of OSA. 11 
Prevalence of PA in patients with OSA 12 
The observed association between aldosterone excess and increased prevalence of cardio- and 13 
cerebrovascular comorbidities, which result into an increased risk for incident mortality, 14 
represents a strong rationale for pursuing the diagnosis of PA.
23,24
 However, since there is not 15 
a typical phenotype to guide the clinicians, the Endocrine Society guideline identifies high-16 
risk groups of hypertensive patients that should be screened for PA, including those with 17 
OSA.
14,25
 While convincing evidence, including a cost-effectiveness study, supports the 18 
recommendation of screening patients with SBP above 150 mmHg, DBP above 100 mmHg, 19 
patients with RH, hypokalaemia or with an adrenal incidentaloma, the evidence for patients 20 
with OSA is limited.
26
  According to a single study, the prevalence of PA in a referred group 21 
of hypertensive patients with OSA resulted to be 34%, but the sample size was small (53 22 
patients) and all the recruited patients with OSA were symptomatic for sleepiness symptoms, 23 
which account only for a subgroup of patients with sleep apnea.
27,28
 24 
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In the HYPNOS study, the prevalence of PA in patients with OSA and requiring CPAP 1 
treatment, resulted to be 8.9%, a figure not significantly different either from the 5.9% 2 
observed in the general hypertensive population of the PATO study or from the 11.2% of the 3 
referred patients from the PAPY study.
21,22
 Interestingly, when considering only the subgroup 4 
of patients without hypokalaemia or SBP ≥ 150 mmHg or DBP ≥ 100 or RH (the main 5 
indications for PA screening), a very low prevalence of 1.5% was detected. 6 
The results of our subgroup analysis, showing that PA prevalence did not increase with the 7 
severity of OSA, that PRA and aldosterone levels were not significantly different in OSA 8 
stages and that severity of OSA was not associated with PA diagnosis, further support the 9 
epidemiological observation that patients affected by OSA do not represent a category of 10 
subjects with high prevalence of PA. The reported results are consistent in both ethnicities of 11 
Caucasian and Chinese patients.   12 
Prevalence of OSA in patients with PA 13 
OSA is a highly prevalent disorder in the general population, with a reported prevalence 14 
comprised between 9 and 38%, considering a cut-off of AHI ≥ 5.29 Studies evaluating the 15 
prevalence of OSA in hypertensive cohorts reported a prevalence from 37 to 48% in 16 
Caucasian patients with hypertension and 70.5% in Chinese hypertensives.
30-33
 In patients 17 
with RH the prevalence is remarkably high, up to 80%, and even higher in patients with 18 
refractory hypertension.
4
 19 
We reported herein for the first time the prevalence of OSA in a large cohort of 207 20 
unselected patients with PA, which resulted to be 67.6% in the overall cohort, 64.4% in 21 
Caucasian and 70.0% in Chinese patients respectively.  22 
To date, the available data on the prevalence of OSA in patients with PA was limited to two 23 
small cohort of less than 50 patients affected by RH, showing a prevalence of 78.1% and 24 
84%, respectively.
2,5
 Moreover, it must be acknowledged that in the study by Gonzaga et al. 25 
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not in all patients the diagnosis of PA was in agreement with the Endocrine Society 1 
recommendations. 2 
In our study, the prevalence of OSA in Caucasian patients with PA appears to be higher than 3 
previously reported, while the prevalence of OSA in Chinese patients with PA was similar to 4 
that reported in Chinese patients with essential hypertension.
30-33
  5 
In agreement with a previous study, a correlation between aldosterone levels and AHI was 6 
present in Caucasian patients with PA, but not in the overall cohort or in the Chinese 7 
subgroup of patients with PA.
5
 8 
The role of ethnic difference in OSA risk factors was previously evaluated by several studies, 9 
particularly focusing on the role of anthropometric differences i  cranio-mandibular anatomy 10 
and different body fat distribution.
34,35
 Furthermore, Asians salt intake is higher than in 11 
Caucasians, together with an augmented salt-sensitivity of blood pressure, potentially 12 
contributing to increased fluid retention.
36
 Therefore, it is possible to speculate that the role of 13 
aldosterone might be less relevant in Chinese ethnicity, because of anatomical predisposing 14 
factors and a high salt intake. 15 
In agreement with our observation, treatment with MR antagonists significantly reduced AHI 16 
and specific treatment of PA, either surgical or medical, reduced the number of apnea and 17 
hypopnea.
10,11,37
 18 
In our study, patients with PA and moderate-severe OSA were older and more likely to be 19 
male than patients with PA and no or mild OSA. They also displayed larger neck 20 
circumference and a worse metabolic profile, confirming the role of sex, obesity and 21 
anatomical characteristics. In Caucasian patients with PA, aldosterone correlates with 22 
moderate-severe OSA even after correction for these confounding variables. This leads to the 23 
hypothesis that in the presence of the known risk factors for OSA, aldosterone can 24 
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independently act as a contributing factor to the development or worsening of OSA in 1 
Caucasian patients with PA.  2 
A potential bidirectional relationship between OSA and diabetes has been postulated since 3 
patients with OSA more often display type 2 diabetes, and diabetic neuropathy can be 4 
associated with alterations of central control of respiration and upper airways neural 5 
reflexes.
38
 Aldosterone excess can play a significant role in this complex interplay since it is 6 
associated with metabolic alterations including type 2 diabetes and play a significant role in 7 
patients with severe OSA by increasing blood pressure and worsening upper airways 8 
congestion.
11,23,39
 9 
The strengths of our study are the large number of recruited patients with PA and with OSA, 10 
the multicenter and multi-ethnic composition of the cohorts, the use of screening, 11 
confirmatory and subtyping test for PA according to the most recent international guideline, 12 
and the systematic use of cardio-respiratory poligraphy to screen for OSA. Furthermore, the 13 
prevalence of PA in patients with OSA was evaluated in a single centre for Caucasians 14 
(Torino) and in a single centre for Chinese (Taipei).  15 
The limits of the current study are: the slightly different cut-offs for screening, confirmatory 16 
and subtype diagnosis in the different centres, the use of different kits for aldosterone, PRA 17 
and renin measurements, the relatively low number of patients with PA with subtype 18 
differentiation in the Chinese group, the lack of a single scoring centre, the lack of sodium 19 
intake and ambulatory blood pressure measurement data. Additionally, the prevalence of 20 
OSA was not assessed in a cohort of patients affected by essential hypertension referred to 21 
our centres and multinomial logistic regression in the Chinese group was partially affected by 22 
the relatively low number of female patients with moderate-severe OSA. 23 
Perspectives 24 
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Collectively, the results of the HYPNOS study challenge the current recommendation of the 1 
Endocrine Society guideline that all patients with arterial hypertension and OSA should be 2 
tested for PA, since a systematic screening would doubtlessly increase medical costs and 3 
consequences of false-positive case detection testing. 4 
Further studies are recommended to better elucidate the potential role of a different ethnicity 5 
on the complex and bidirectional interplay between aldosterone and OSA and whether a 6 
different response in OSA severity is present after PA specific treatment.  7 
 8 
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Novelty and Significance:  1 
What Is New? 2 
 The prevalence of PA among patients with hypertension and OSA is not different 3 
from the prevalence reported in primary care or referral centres. 4 
 The prevalence of PA among patients without any other indications, other than OSA 5 
diagnosis, for PA screening is low. 6 
 The prevalence of OSA in patients affected by PA is high and aldosterone correlates 7 
with AHI in moderate-severe OSA in Caucasian patients with hyperaldosteronism. 8 
What Is Relevant?  9 
 For PA screening, patients affected by OSA should follow the same recommendations 10 
of the general hypertensive population.  11 
 Results of the present study challenge the current recommendations of the Endocrine 12 
Society guideline for PA screening.  13 
Summary 14 
 Patients affected by OSA do not represent a category at high risk for PA, however 15 
aldosterone can independently act as a contributing factor to the development or 16 
worsening of OSA in Caucasian patients with PA. 17 
 Ethnic differences might play a role in the interplay between OSA and aldosterone 18 
overproduction. 19 
Figure legends 20 
Figure 1. Prevalence of primary aldosteronism in patients with obstructive sleep apnea 21 
(A) Prevalence of primary aldosteronism (PA) in the overall group of patients affected by 22 
obstructive sleep apnea (OSA). PA diagnosis is divided according to subtype diagnosis: 23 
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aldosterone producing adenoma (APA), idiopathic hyperaldosteronism (IHA), undetermined 1 
subtype diagnosis. (B) Prevalence of PA in Caucasian patients with OSA. (C) Prevalence of 2 
PA in Chinese patients with OSA. 3 
Figure 2. Prevalence of obstructive sleep apnea in patients with primary aldosteronism. 4 
(A) Prevalence of obstructive sleep apnea (OSA) in the overall group of patients affected by 5 
primary aldosteronism (PA). OSA diagnosis is dived according to OSA severity: OSA mild 6 
(AHI ≥ 5 and < 15), moderate (AHI ≥ 15 and < 30), severe (AHI ≥ 30). (B) Prevalence of 7 
OSA in Caucasian patients with PA. (C) Prevalence of OSA in Chinese patients with PA. 8 
 9 
Tables 10 
Table 1. Clinical and biochemical parameters of patients with diagnosis of OSA or PA  11 
Parameters PA (n = 207) OSA (n = 203) 
Age (years) 50 ± 10 50 ± 9 
Ethnicity  
Caucasian  
Chinese  
African descent  
 
 
104 (50.2) 
100 (48.3) 
3 (1.5) 
 
 
102 (50.2) 
101 (49.8) 
- 
Sex 
Male 
Female  
 
116 (56.0) 
91 (44.0) 
 
159 (78.3) 
44 (21.7) 
BMI (kg/m
2
)  26.3 ± 4.1 32.2 ± 6.5 
Neck circumference (cm)  38 ± 4 42 ± 4 
Waist circumference (cm) 
Male 
Female 
 
 
97.6 ±10.5 
88.4 ± 11.9 
 
107.3 ± 15.7 
104.3 ± 18.4 
Central Obesity 
No 
Yes 
 
54 (26.1) 
153 (73.9) 
 
18 (8.9) 
185 (91.1) 
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SBP* (mmHg)  157 ± 16 152 ± 19 
DBP* (mmHg)  97 ± 11 94 ± 12 
Antihypertension medication 
(defined daily dose) 
1.10 (0.00-3.00) 1.83 (1.00-3.00) 
Fasting glucose (mmol/l)  5.41 ± 1.39 6.44 ± 2.14 
Total cholesterol (mmol/l)  4.52 ± 1.02 5.07 ± 1.11 
LDL (mmol/l)  2.53 ± 0.85 3.10 ± 1.06 
HDL (mmol/l)  1.28 ± 0.42 1.15 ± 0.36 
Triglycerides (mmol/l)  1.22 (0.83-1.90) 1.48 (1.08-2.14) 
GFR (ml/min/1.73m
2
)  103 (84-122) 112 (94-137) 
Sodium (mmol/l)  143 ± 3 140 ± 3 
Potassium (mmol/l)  3.5 ± 0.6 4.0 ± 0.5 
Diabetes  
No 
IFG 
Yes 
 
161 (77.8) 
20 (9.7) 
26 (12.6) 
 
88 (43.3) 
49 (24.1) 
66 (32.5) 
Metabolic Syndrome  
No 
Yes 
 
124 (59.9) 
83 (40.1) 
 
46 (22.7) 
157 (77.3) 
PA = primary aldosteronism; OSA = obstructive sleep apnea; BMI = body mass index; SBP 1 
= systolic blood pressure; DBP = diastolic blood pressure; LDL = low density lipoproteins; 2 
HDL = high density lipoproteins; GFR= glomerular filtration rate; IFG = impaired fasting 3 
glucose. *at first visit. Values are mean ± SD, median (IQR) or absolute number (%).  4 
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Table 2. Clinical and biochemical parameters of patients affected by OSA with and without PA and patients affected by PA with AHI < 
or ≥ 15 
 Patients with OSA (n = 203)  Patients with PA (n = 207)  
Parameters Non PA (n=185) PA (n=18) P  value AHI < 15 (n = 123)  AHI ≥ 15 (n = 84)  P  value 
PRA (ng/mL/h)  1.90 (1.09-4.31) 0.42 (0.18-0.53) < 0.001 0.3 (0.2-0.5) 0.1 (0.1-0.4) 0.072 
Direct renin (mU/L)  - - - 2.1 (1.0-5.6) 2.0 (0.7-4.5) 0.402 
Aldosterone (pmol/L)  419 (294-619) 865 (568-1429) < 0.001 655 (455-965) 759 (495-1101) 0.098 
AHI  37 (23-66) 38 (17-52) 0.607 4.4 (1.4-8.5) 28.1 (19.8-44.1) < 0.001 
ESS  8 (5-12) 8 (5-12) 0.626 6 (3-8) 6 (4-10) 0.472 
Age (years) 50 ± 10 50 ± 9 0.984 48 ± 10 53 ± 9 0.001 
Sex 
Male 
Female  
 
143 (77.3) 
42 (22.7) 
 
16 (88.9) 
2 (11.1) 
0.255  
51 (41.5) 
72 (58.5) 
 
65 (77.4) 
19 (22.6) 
< 0.001 
BMI (kg/m
2
)  32.1 ± 6.7 32.8 ± 4.5 0.682 25.7 ± 4.2 27.3 ± 3.8 0.004 
Neck circumference (cm)  42 ± 4 44 ± 2 0.072 38 ± 4 40 ± 4 < 0.001 
Waist circumference (cm) 
Male 
Female  
 
107.2 ± 16.3 
103.8 ± 18.7 
 
 
107.9 ± 9.3 
114.0 ± 1.4 
 
0.868 
0.450 
 
95.4 ± 9.6 
88.2 ± 12.9 
 
99.2 ± 10.9 
89.0 ± 7.4 
 
0.049 
0.800 
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Central Obesity 
No 
Yes 
 
18 (9.7) 
167 (90.3) 
 
0 (0.0) 
18 (100.0) 
0.166  
38 (30.9) 
85 (69.1) 
 
16 (19.0) 
68 (81.0) 
0.057 
SBP* (mmHg)  151 ± 19 168 ± 16 < 0.001 155 ± 16 160 ± 16 0.040 
DBP* (mmHg)  94 ± 12 100 ± 11 0.030 96 ± 11 98 ± 11 0.098 
Antihypertensive 
medications  
(defined daily dose) 
1.50 (0.71-2.53) 2.75 (1.37-4.0) 0.022 1.00 (0.00-3.00) 1.15 (0.00-2.50) 0.653 
Fasting glucose (mmol/l)  6.43 ± 2.15 6.56 ± 2.00 0.807 5.12 ± 0.93 5.87 ± 1.82 0.001 
Total cholesterol (mmol/l)  5.10 ± 1.12 4.75 ± 0.90 0.210 4.56 ± 0.98 4.47 ± 1.09 0.556 
LDL (mmol/l)  3.14 ± 1.06 2.75 ± 1.00 0.137 2.58 ± 0.83 2.46 ± 0.88 0.337 
HDL (mmol/l)  1.15 ± 0.36 1.15 ± 0.27 0.999 1.34 ± 0.40 1.19 ± 0.44 0.015 
Triglycerides (mmol/l)  1.48 (1.09-2.11) 1.61 (1.02-2.82) 0.645 1.16 (0.81-1.70) 1.48 (0.99-2.28) 0.004 
GFR (ml/min/1.73m
2
)  110 (94-137) 125 (102-140) 0.420 105 (87-122) 99 (81-117) 0.190 
Sodium (mmol/l)  140 ± 3 141 ± 4 0.111 142 ± 3 144 ± 3 0.011 
Potassium (mmol/l)  4.0 ± 0.5 3.6 ± 0.5 0.002 3.6 ± 0.6 3.5 ± 0.6 0.213 
Diabetes  
No 
IFG 
Yes 
 
81 (43.8) 
43 (23.2) 
61 (33.0) 
 
7 (38.9) 
6 (33.3) 
5 (27.8) 
0.632  
105 (85.4) 
11 (8.9) 
7 (5.7) 
 
56 (66.7) 
9 (10.7) 
19 (22.6) 
0.001 
Fo
r H
yp
ert
en
sio
n P
ee
r R
ev
iew
. D
o n
ot 
dis
trib
ute
. D
es
tro
y a
fte
r u
se
.
 
 
 
28 
 
Metabolic Syndrome  
No 
Yes  
 
42 (22.7) 
143 (77.3) 
 
4 (22.2) 
14 (77.8) 
0.963  
79 (64.2) 
44 (35.8) 
 
45 (53.6) 
39 (46.4) 
0.125 
CV events  
No 
Yes 
 
161 (87.0) 
24 (13.0) 
 
15 (83.3) 
3 (16.7) 
0.660  
114 (92.7) 
9 (7.3) 
 
74 (88.1) 
10 (11.9) 
0.262 
PA = primary aldosteronism, OSA = obstructive sleep apnea, AHI = apnea hypopnea index, PRA = plasma renin activity, ESS = Epworth 
Sleepiness Scale, BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, LDL = low density lipoproteins, HDL 
= high density lipoproteins, GFR= glomerular filtration rate, IFG = impaired fasting glucose, CV = cardiovascular. *at first visit. Values are 
mean ± SD, median (IQR) or absolute number (%). P values are calculated with Student’s t test, Mann-Whitney U test or chi square test.
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Table 3. Clinical and biochemical parameters of patients with OSA stratified by 
ethnicity 
Parameters Caucasian  
(n=102) 
Chinese  
(n=101) 
P-value  
AHI  27.7 (16.8-42.0) 55.7 (32.6-80.4) < 0.001 
ESS  6 (3-8) 11 (8-16) < 0.001 
PRA (ng/mL/h)  1.3 (0.5-2.5) 2.5 (1.1-5.1) < 0.001 
Aldosterone (pmol/L)  449 (298-681) 428 (310-624) 0.970 
Age (years) 53 ± 8 47 ± 10 <0.001 
Sex 
Male 
Female  
 
75 (73.5) 
27 (26.5) 
 
84 (83.2) 
17 (16.8) 
0.096 
BMI (kg/m
2
)  30.8 ± 5.8 33.5 ± 6.9 0.003 
Neck circumference (cm)  43 ± 3 42 ± 4 0.054 
Waist circumference (cm)  
Male 
Female 
 
105.5 ± 10.6  
106.0 ± 20.8 
 
108.7 ± 19.0  
101.6 ± 13.9 
 
0.184 
0.446 
Central Obesity 
No 
Yes 
 
13 (12.7) 
89 (87.3) 
 
5 (5.0) 
96 (95.0) 
0.051 
SBP* (mmHg)  158 ± 16 146 ± 20 <0.001 
DBP* (mmHg)  95 ± 9 93 ± 15 0.501 
Antihypertensive medications 
(defined daily dose) 
1.91 (1.00-3.07) 1.50 (0.50-2.50) 0.452 
Fasting glucose (mmol/l)  5.81 ± 1.45 7.08 ± 2.50 <0.001 
Total cholesterol (mmol/l)  5.50 ± 1.03 4.64 ± 1.02 <0.001 
LDL (mmol/l)  3.40 ± 1.00 2.80 ± 1.03 <0.001 
HDL (mmol/l)  1.29 ± 0.36 1.01 ± 0.29 <0.001 
Triglycerides (mmol/l)  1.46 (1.04-2.08) 1.51 (1.16-2.32) 0.266 
GFR (ml/min/1.73m
2
)  115 (100-136) 107 (91-148) 0.388 
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Sodium (mmol/l)  141 ± 3 138 ± 3 <0.001 
Potassium (mmol/l)  4.1 ± 0.4 3.8 ± 0.5 <0.001 
Diabetes  
No 
IFG 
Yes 
 
68 (66.7) 
22 (21.6) 
12 (11.8) 
 
20 (19.8) 
27 (26.7) 
54 (53.5) 
< 0.001 
Metabolic Syndrome  
No 
Yes 
 
36 (35.3) 
66 (64.7) 
 
10 (9.9) 
91 (90.1) 
< 0.001 
OSA = obstructive sleep apnea, AHI = apnea hypopnea index, PRA = plasma renin activity, 
ESS = Epworth Sleepiness Scale, BMI = body mass index, SBP = systolic blood pressure, 
DBP = diastolic blood pressure, LDL = low density lipoproteins, HDL = high density 
lipoproteins, GFR= glomerular filtration rate, IFG = impaired fasting glucose. *at first visit 
Values are mean ± SD, median (IQR) or absolute number (%). P values are calculated with 
Student’s t test, Mann-Whitney U test or chi square test. 
 
 
Table 4. Clinical and biochemical parameters of patient  with PA stratified by ethnicity 
Parameters Caucasian  
(n=104) 
Chinese  
(n=100) 
P  value  
AHI  8.5 (2.2-18.1) 14.5 (3.4-34.6) 0.022 
ESS  6 (3-8) 6 (4-10) 0.179 
OSA 
No 
Mild  
Moderate 
Severe  
 
37 (35.6) 
32 (30.8) 
24 (23.1) 
11 (10.6) 
 
30 (30.0) 
22 (22.0) 
20 (20.0) 
28 (28.0) 
0.016 
PRA (ng/mL/h)  0.25 (0.1-0.5) - - 
Direct renin (mU/L)  2.6 (2.0-4.3) 1.7 (0.5-5.0) 0.005 
Aldosterone (pmol/L)  671 (465-968) 699 (473-1078) 0.480 
Age (years) 52 ± 10 47 ± 10 0.001 
Sex 
Male 
Female  
 
64 (61.5) 
40 (38.5) 
 
50 (50.0) 
50 (50.0) 
0.097 
BMI (kg/m
2
)  27.3 ± 4.4 25.4 ± 3.5 0.001 
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Neck circumference (cm)  40 ± 4 36 ± 5 < 0.001 
Waist circumference (cm) 
Male 
Female 
 
99.7 ± 9.8 
93.3 ± 14.7 
 
94.7 ± 10.8 
84.4 ± 7.4 
 
0.012 
0.001 
Central Obesity 
No 
Yes 
 
26 (25.0) 
78 (75.0) 
 
28 (28.0) 
72 (72.0) 
0.627 
SBP* (mmHg)  158 ± 15 155 ± 18 0.180 
DBP* (mmHg)  97 ± 9 96 ± 12 0.401 
Antihypertension medication 
(defined daily dose) 
2.00 (1.00-3.62) 0.00 (0.00-1.07) < 0.001 
Fasting glucose (mmol/l)  5.33 ± 1.06 5.51 ± 1.72 0.384 
Total cholesterol (mmol/l)  4.81 ± 1.06 4.19 ± 0.85 < 0.001 
LDL (mmol/l)  2.80 ± 0.86 2.23 ± 0.73 < 0.001 
HDL (mmol/l)  1.38 ± 0.42 1.15 ± 0.38 < 0.001 
Triglycerides (mmol/l)  1.15 (0.80-1.84) 1.39 (0.96-2.14) 0.047 
GFR (ml/min/1.73m
2
)  103 (86-127) 101 (81-119) 0.159 
Sodium (mmol/l)  141 ± 2 145 ± 3 < 0.001 
Potassium (mmol/l)  3.6 ± 0.5 3.4 ± 0.6 0.006 
Diabetes  
No 
IFG 
Yes 
 
81 (77.9) 
17 (16.3) 
6 (5.8) 
 
78 (78.0) 
2 (2.0) 
20 (20.0) 
< 0.001 
Metabolic Syndrome  
No 
Yes 
 
55 (52.9) 
49 (47.1) 
 
67 (67.0) 
33 (33.0) 
0.040 
OSA = obstructive sleep apnea, AHI = apnea hypopnea index, PRA = plasma renin activity, 
ESS = Epworth Sleepiness Scale, BMI = body mass index, SBP = systolic blood pressure, 
DBP = diastolic blood pressure, LDL = low density lipoproteins, HDL = high density 
lipoproteins, GFR= glomerular filtration rate, IFG = impaired fasting glucose. *at first visit 
Values are mean ± SD, median (IQR) or absolute number (%). P values are calculated with 
Student’s t test, Mann-Whitney U test or chi square test. 
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